Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RLAYthis companyRelay Therapeutics, Inc.	$19.69	-5.25×	2.56×	94.54×	-5.13×	-104.1%	76.8%	-1971.6%	-1800.6%	-48.8%	-50.5%	-16.2%	0.06×	0.19×	0×	22.61×	0.0%	3	26.32	2	C
AVBPArriVent BioPharma, Inc.	$13.98	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
ERASErasca, Inc.	$15.04	-8.45×	3.24×	0×	-8.47×	-99.3%	0.0%	0.0%	0.0%	-38.3%	-35.3%	-9.1%	0.14×	0.22×	0×	10.04×	0.0%	1	35.36	1	C-
IDYAIDEAYA Biosciences, Inc.	$31.52	-27.01×	2.99×	13.99×	-19.22×	-438.0%	-43.9%	-72.8%	-52.0%	-11.1%	-15.2%	-2.4%	0.03×	0.55×	0×	11.34×	0.0%	1	14.74	2	C
KYMRKymera Therapeutics, Inc.	$133.83	-21.09×	4.16×	167.51×	-20.76×	-99.8%	100.0%	-891.3%	-794.4%	-19.7%	-20.9%	-3.6%	0.05×	0.91×	-1,403.21×	10.47×	0.0%	4	41.46	1	C-
NRIXNurix Therapeutics, Inc.	$16.09	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
Peer median	—	-8.45×	2.99×	13.99×	-8.47×	-99.8%	0.0%	-72.8%	-52.0%	-38.3%	-35.3%	-9.1%	0.05×	0.55×	0×	10.47×	0.0%	2	14.74	2	—